Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Publication year range
1.
Environ Pollut ; 249: 267-276, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30897466

ABSTRACT

Cyanotoxins from toxic blooms in lakes or eutrophic reservoirs are harmful to several organisms including zooplankton, which often act as vectors of these secondary metabolites, because they consume cyanobacteria, bioaccumulate the cyanotoxins and pass them on along the food chain. Microcystins are among the most commonly found cyanotoxins and often cause zooplankton mortality. Although cyanobacterial blooms are common and persistent in Mexican water bodies, information on the bioaccumulation of cyanotoxins is scarce. In this study we present data on the bioaccumulation of cyanotoxins from Planktothrix agardhii, Microcystis sp., Cylindrospermopsis raciborskii and Dolichospermum planctonicum blooms in the seston (suspended particulate matter more than 1.2 µm) by zooplankton and fish (tilapia (Oreochromis niloticus) and mesa silverside (Chirostoma jordani) samples from Lake Zumpango (Mexico City). The cyanotoxins were extracted from the seston, zooplankton and fish tissue by disintegration using mechanical homogenization and 75% methanol. After extraction, microcystins were measured using an ELISA kit (Envirologix). Concentration of microcystins expressed as equivalents, reached a maximum value of 117 µg g-1 on sestonic samples; in zooplankton they were in the range of 0.0070-0.29 µg g-1. The dominant zooplankton taxa included Acanthocyclops americanus copepodites, Daphnia laevis and Bosmina longirostris. Our results indicate twice the permissible limits of microcystins (0.04 µg kg-1 d-1) for consumption of cyanobacterial products in whole fish tissue of Chirostoma jordani. The data have been discussed with emphasis on the importance of regular monitoring of water bodies in Mexico to test the ecotoxicological impacts of cyanobacterial blooms and the risk that consumption of products with microcystins could promote.


Subject(s)
Environmental Monitoring , Fishes/metabolism , Lakes/microbiology , Microcystins/metabolism , Water Pollutants, Chemical/metabolism , Zooplankton/metabolism , Animals , Copepoda/metabolism , Cyanobacteria/metabolism , Cylindrospermopsis , Daphnia/metabolism , Food Chain , Lakes/chemistry , Mexico , Microcystis/metabolism , Seafood/analysis
2.
Toxicon ; 139: 45-53, 2017 Dec 01.
Article in English | MEDLINE | ID: mdl-28958830

ABSTRACT

Unlike temperate regions, tropical ecosystems are characterized by high temperatures (>18 °C) all year, promoting blooms of cyanobacteria which often produce secondary metabolites toxic to zooplankton. Nabor Carillo and the Recreational Lake are part of the saline, Lake Texcoco, in Central Mexico which is filled nowadays with treated waste water. Both water bodies are dominated by Planktothrix, Anabaenopsis, Spirulina and Microcystis. In this study we present the concentration of microcystins in these waterbodies over an annual cycle. We also evaluated the chronic effects of cyanobacterial crude extracts from both lakes on two clones of the rotifer Brachionus calyciflorus, one from Nabor Carrillo Lake and the other from a canal in the shallow, Lake Xochimilco. The experiments on population growth were performed, beginning with 10 individuals per container for each of the following treatments: control (no crude extract), concentrated crude extract, and diluted crude extract (50:50) with moderately hard water and Chlorella vulgaris in a concentration of 0.5 × 106 cells ml-1. The cyanotoxin levels were measured using an ELISA test and ranged between 0.20 and 2.4 µg L-1 in the lake water. The results showed that the Recreational Lake extracts were more toxic, killing the rotifers in less than five days. The r values ranged from -1.74 to 0.48 in the presence of the crude extracts and 0.16 and 0.24 in the controls. The results have been discussed with emphasis on the importance of conducting regular studies to test ecotoxicological impacts of cyanobacterial blooms in tropical waters.


Subject(s)
Complex Mixtures/toxicity , Microcystins/analysis , Rotifera/drug effects , Animals , Chlorella , Cyanobacteria/chemistry , Eutrophication , Lakes , Mexico , Population Growth , Rotifera/growth & development , Water Pollutants, Chemical/toxicity
7.
Ecotoxicology ; 24(1): 85-93, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25300505

ABSTRACT

In this study we evaluated the toxicological effects of crude extracts of Dolichospermum planctonicum on Plationus patulus (Rotifera) and Ceriodaphnia cornuta (Cladocera). The active compound from the laboratory-cultured cyanobacteria was extracted by lyophilizing it at -70 °C for 48 h, after which the sample was thawed. The cycle was repeated five times, and between each cycle the cells were sonicated to lyse them. Using the extract of Anabaena, experiments of population growth and life table demography of the two zooplankton species were compared in media with and without (controls) the cyanotoxins. In both experiments two toxic concentrations diluted in US EPA medium were used, one in a 5:15 proportion, and the other in a 2.5:17.5. We found that the rotifers were more resistant to the toxicants than the cladocerans. Their population growth rates ranged from 0.11 d(-1) in controls to 0.08 d(-1) in the presence of the crude extracts for P. patulus and from 0.18 in controls to -0.27 in the presence of the crude extracts for C. cornuta. The crude extract also had a significant negative impact on the demographic parameters, adversely affecting reproduction more than survival. The data have been discussed with emphasis on the importance of further research using cyanobacterial crude extracts.


Subject(s)
Cladocera/drug effects , Complex Mixtures/toxicity , Cyanobacteria/chemistry , Rotifera/drug effects , Animals , Cladocera/growth & development , Eutrophication , Rotifera/growth & development , Water Pollutants, Chemical/toxicity
8.
Transpl Int ; 22(2): 198-206, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18796000

ABSTRACT

Rapid bone loss and high rates of fractures occur following liver transplantation. To analyze the effect of intravenous pamidronate on bone loss after liver transplantation. A randomized, double-blind, placebo-controlled study was performed. Seventy-nine patients were randomized to two groups of treatment: the pamidronate group (n = 38) was treated with 90 mg/IV of pamidronate within the first 2 weeks and at 3 months after transplantation; the placebo group (n = 41) received glucose infusions at the same time points. All patients received calcium and vitamin D. Bone mineral density (BMD) at the lumbar spine (L(2)-L(4)) and proximal femur using dual energy X-ray absorptiometry and also spinal X-rays were performed before, and at 6 and 12 months after liver transplantation. Biochemical and hormonal determinations were performed previous to transplantation, at 24 h before and after treatment, as well as at 6 and 12 months after liver transplantation. At 12 months after transplantation, there were significant differences in lumbar BMD changes (6 months: pamidronate 1.6% vs. placebo 0.8%, P = NS; 12 months: pamidronate 2.9% vs. placebo 1%, P < 0.05). Femoral neck BMD decreased in the pamidronate- and placebo groups during the first 6 months (6 months: pamidronate -3.1% vs. placebo -2.9%, P = NS; 12 months: pamidronate -3.2% vs. placebo -3.1%, P = NS). BMD at the trochanter remained stable in the pamidronate group, whilst a reduction was observed in the placebo group at 6 months (6 months: pamidronate -0.7% vs. placebo -3.7%, P < 0.05; 12 months: pamidronate -0.5% vs. placebo -1.2%, P = NS). Moreover, no significant differences in the incidence of fractures, serum parathyroid hormone and serum 25-hydroxyvitamin D values between both groups were found. Pamidronate did not increase the risk of serious adverse events. The results of this study show that 90 mg of intravenous pamidronate within the first 2 weeks and at 3 months following liver transplantation preserve lumbar bone mass during the first year, without significant adverse events. However, pamidronate does not reduce bone loss at the femoral neck and furthermore it does not reduce skeletal fractures.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Resorption/prevention & control , Diphosphonates/therapeutic use , Liver Transplantation/adverse effects , Adult , Aged , Bone Density/drug effects , Bone Density Conservation Agents/pharmacology , Bone Resorption/etiology , Diphosphonates/pharmacology , Double-Blind Method , Female , Humans , Male , Middle Aged , Pamidronate , Prospective Studies , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...